Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark’s Digital Asthma Inhaler: Is It Really A Roaring Success?

Executive Summary

Just months into its launch, over 100,000 patients in India are said to be using Glenmark’s “Digihaler” for asthma and chronic obstructive pulmonary disorder (COPD) medication. But some key opinion leaders appear unconvinced of the disruptive potential of the firm’s next generation digital dose inhaler.

Advertisement

Related Content

Glenmark Wins ‘Milestone’ US Nod For COPD Trial In Innovation Push
Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel